Conference Coverage
about 18 hours ago
2026 Elevate Derm Summer Conference Day 3 RecapLatest News
Videos
Advertisement
Shorts
0:29
Stop Believing This Hair Washing Myth
5 hours ago
by
Oyetewa Asempa, MD, FAAD
0:22
The #1 thing every medical professional needs
21 hours ago
by
Justin Love, PA-C
0:23
A simple way for doctors to connect with patients
a day ago
by
Victoria Garcia-Albea, NP
0:48
What I'd do if I won the lottery: Pediatric Derm Edition
2 days ago
by
Lisa Swanson, MD, FAAD
1:20
It Takes a Village: How Clinicians Can Support Patients With TSW
2 days ago
by
Renata Block, DMSc, MMS, PA-C(+1 more)
0:48
The Accutane Alternative You Need
3 days ago
by
Aaron S. Farberg, MD
0:53
Minimal Adverse Events Associated With Tapinarof Cream
3 days ago
by
Linda Stein Gold, MD
0:49
"Unscented" Isn't Fragrance-Free — Here's Why It Matters
4 days ago
by
Andrew C. Krakowski, MD(+1 more)
0:19
Why Dermatopathology Is a Team Sport
4 days ago
by
Adnan Mir, MD, PhD
0:17
The Hidden Stuggle Every Derm Nurse Feels
5 days ago
by
Dr. Kimberly Madison, DNP,(+1 more)
GEP-Guided Treatment for Melanoma & SCC Management
New Insights in Management of Moderate Hidradenitis Suppurativa
Discover Dermatology Times NP/PA Connect™!
Personalizing Treatment for Difficult Atopic Dermatitis Cases
Connect With Dermatology Times® Wherever You Scroll
Podcasts
Dermatology Times Digital Edition
Learn more about the in-depth topics covered in the July 2026 digital issue of Dermatology Times.
In July's letter from the editor in chief, Christopher Bunick, MD, PhD, breaks down why dermatology clinicians should be skilled in wound care.
In this Cosmetics Conundrums column, learn why the cosmeceutical vehicle drives 80% of skin care results, shaping feel, film, and active delivery for visible benefits.
RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.
Jane Yoo, MD, MPP, FAAD, shares expert tips to treat melasma in skin of color regarding sunscreen shades, hydroquinone breaks, TXA choices, and safer laser/peel decisions.
New trends around cheeky swimwear and tanning myths are leading to rising rates of melanomas in sensitive areas; read July's cover story to learn more.
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.
Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.
New data show that nearly two-thirds of Sun Bus participants had never visited a dermatologist, highlighting persistent gaps in access to skin cancer care.
Continuing Medical Education
All News
Advertisement
Advertisement
Two phase 3 trials of Pfizer's ritlecitinib met co-primary end points for facial and total repigmentation in nonsegmental vitiligo at week 52, prompting plans for global regulatory filings.
In this Cosmetics Conundrums column, learn why the cosmeceutical vehicle drives 80% of skin care results, shaping feel, film, and active delivery for visible benefits.
RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.
Jane Yoo, MD, MPP, FAAD, shares expert tips to treat melasma in skin of color regarding sunscreen shades, hydroquinone breaks, TXA choices, and safer laser/peel decisions.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
San Diego meeting highlights inflammatory dermatoses, skin cancer, alopecia, and emerging therapeutic advances
July's FDA news was quiet, but an infant AD filing, JAK-refractory alopecia data, and a new device clearance hint at what's next.
Catch Up on Coverage From Day 1 of the 3rd Annual Elevate-Derm Summer Conference
Dermatology Times is looking back on the top stories in dermatology from the month of July.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of July.
Advertisement
Phase 1 results show Bambusa Therapeutics’ BBT001 quickly reduces atopic dermatitis and itch, sustains type 2 biomarker suppression, and may enable quarterly dosing.
As we wrap up July, explore the new sunscreen ingredient approval, debunk summer skin care myths, and learn how UV damage and therapies are shaping skin cancer prevention today.
Our July issue tackles melanoma surgery challenges, melasma in skin of color, new bemotrizinol sunscreen, atopic dermatitis breakthroughs, and billing insights from Whitney Hovenic, MD, Joseph Gatti, DMSc, Rivkah Epstein, PA-C, and more.
Catch up on all of our coverage from this year's Society for Pediatric Dermatology annual meeting.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Advertisement
Advertisement